Clinical Trial Update: Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study [Phase 2]

View source ↗

Summary

Phase 2 BeGIN study results evaluate the glutaminase inhibitor telaglenastat hydrochloride in advanced and metastatic malignant solid tumors, including NF1-muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumors
• Neurofibromatosis Type 1-associated Malignant Peripheral Nerve Sheath Tumor
• Unresectable Malignant Solid Tumors

Drugs mentioned

• Telaglenastat hydrochloride (telaglenastat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-01